Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04457245 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
A Phase 3 study, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
NCT04457245: Clinical Trial Phase 3 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT04457245 is a Phase 3 study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 54 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04457245, a Phase 3 study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
Study Summary
This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based dRT, may improve radiation therapy planning and patient selection for dRT, and potentially improve its outcome compared to dRT without PSMA PET (standard dRT).
Primary Outcome
Will be measured as progression-free survival after initiation of dRT. Progression is defined as (whichever occurs first): A biochemical recurrence defined as a rise by 2 ng/mL or more above the nadir prostate specific antigen (PSA) (defined as the lowest PSA achieved) after radiotherapy with or without short-term hormonal therapy, appearance of metastasis or loco-regional recurrence (diagnosed by any imaging or biopsy), initiation of any new salvage therapy or death from any cause. Survival cur
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- RADIATION Radiation Therapy
- OTHER Fluorine F 18 DCFPyL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 3 |
Why NCT04457245 stopped before completion
NCT04457245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography is the first listed.
NCT04457245 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04457245 about?
NCT04457245 is a clinical study titled "Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer". This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based dRT, may improve radiation therapy planning and patient selection for dRT, and potentially improve its outcome compared...
What is the current status of trial NCT04457245?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2020-08-14. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT04457245?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Radiation Therapy (RADIATION), Fluorine F 18 DCFPyL (OTHER).
Who is sponsoring clinical trial NCT04457245?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04457245's enrollment target sits among peer trials
54 1838th of 2000 higher than 162 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI